Drug Metabolizing Enzymes in the Perinatal and Neonatal Period: Differences in the Expression and Activity

Author(s): Laura Cuzzolin

Journal Name: Current Drug Metabolism

Volume 14 , Issue 2 , 2013

Become EABM
Become Reviewer
Call for Editor


Physiological changes occurring perinatally and in the first month of life can affect the answer to a pharmacological treatment and the individual response to a drug in terms of efficacy and toxicity is highly variable in the neonatal population. Among potential causes for such variability, differences in drug metabolism may have a great impact.

This article aims to review qualitative and quantitative differences in drug metabolizing enzymes in neonates, since both phase I and phase II metabolic pathways are immature at birth and subject to maturational changes in the first period of extrauterine life.

Moreover, clinical implications will be discussed.

Keywords: Newborns, drugs, enzymes, Drug Metabolizing Enzymes, Perinatal, Neonatal Period, toxicity, phase II, CYP2C, CYP3A5, Sulfation

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [167 - 173]
Pages: 7
DOI: 10.2174/1389200211314020003

Article Metrics

PDF: 38